Cargando…
Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report
INTRODUCTION: Currently, the options are limited for the treatment of patients who have failed 2 lines of chemotherapy for advanced lung squamous cell carcinoma (SCC). Recently, nivolumab, a fully human IgG4 programmed death 1 immune checkpoint inhibitor antibody, was approved to treat patients with...
Autores principales: | Pi, Guoliang, He, Hanping, Bi, Jianping, Li, Ying, Li, Yanping, Zhang, Yong, Wang, Mingwei, Han, Guang, Lin, Chi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059083/ https://www.ncbi.nlm.nih.gov/pubmed/27749580 http://dx.doi.org/10.1097/MD.0000000000005077 |
Ejemplares similares
-
Exploration of prognostic biomarkers in head and neck squamous cell carcinoma microenvironment from TCGA database
por: Li, Ying, et al.
Publicado: (2023) -
A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019) -
Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report
por: Chen, Yu-Hsiu, et al.
Publicado: (2017) -
Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017) -
Metastatic spread of solid subtype lung adenocarcinoma to the small intestine with anemia and melena: A case report
por: Ying, Xiaofang, et al.
Publicado: (2017)